<DOC>
	<DOCNO>NCT02994394</DOCNO>
	<brief_summary>To assess bioequivalence OPC-41061 OD tablets OPC-41061 conventional tablet 15 30 mg healthy adult male subject .</brief_summary>
	<brief_title>A Study OPC-41061 Orally Disintegrating ( OD ) Tablets Using 2 Different Formulations 2 Dosing Regimens Healthy Adult Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>Body weight least 50.0 kg BMI [ body weight kg / ( height ) 2 ] least 17.6 kg/m2 less 25.0 kg/m2 Judged investigator subinvestigator capable provide write informed consent prior start trialrelated procedure capable comply trial procedure study . Judged investigator , subinvestigator , sponsor clinically significant abnormality result screen examination ( include notable deviation site 's standard value ) medical history could place subject risk affect evaluation drug absorption , distribution , metabolism , excretion History alcohol drug dependence abuse within 2 year prior trial History current infection hepatitis acquire immunodeficiency syndrome ( AIDS ) carrier hepatitis B positive surface antigen ( HBsAg ) , antihepatitis C virus ( HCV ) , human immunodeficiency virus ( HIV ) , syphilis base result Treponema pallidum ( TP ) antibody test rapid plasma reagin ( RPR ) test History severe drug allergy Positive result alcohol screen test urine drug screen test time screen examination trial site admission Use investigational medicinal product ( IMP ) within 120 day prior Period 1 IMP administration Consumption food beverage contain St. John 's wort within 14 day prior Period 1 IMP administration Consumption food beverage contain grapefruit , Seville orange , star fruit within 7 day prior Period 1 IMP administration Judgment investigator subinvestigator subject participate study reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>